

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of the claims in this application:

**Listing of the Claims:**

Claims 1–98. (Canceled).

<sup>1</sup>  
~~99.~~ (Currently Amended) A method of diagnosing lung, <sup>pancreatic, or esophageal</sup> ~~pancreatic, or~~ esophageal cancer, comprising detecting expression of a tumor-associated antigen in a biological sample, wherein the tumor-associated antigen is selected from the group consisting of:

- (i) the polypeptide of SEQ ID NO: 16; and
- (ii) the polypeptide encoded by the nucleic acid of SEQ ID NO: 7,

wherein detection of the tumor-associated antigen in a biological sample isolated from a patient in an amount greater than an amount of the tumor-associated antigen in a normal biological sample indicates the presence of cancer.

<sup>2</sup>  
~~100.~~ (Previously Presented) The method of claim ~~99~~, <sup>lung, pancreatic, or esophageal</sup> in which the detection <sup>1</sup> comprises:

- (i) contacting the biological sample with an antibody which binds specifically to the tumor-associated antigen; and
- (ii) detecting a complex formed between the antibody and the tumor-associated antigen.

101. (Canceled).

<sup>3</sup>  
~~102.~~ (Previously Presented) The method of claim ~~100~~, <sup>2</sup> wherein the antibody is labeled with a detectable marker.

4

3

~~103.~~ (Previously Presented) The method of claim ~~102~~, wherein the detectable marker is a radioactive marker or an enzymatic marker.

5

1

~~104.~~ (Previously Presented) The method of claim ~~99~~, wherein the biological sample comprises body fluid or body tissue.

105-115. (Canceled).